Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Leases (2017 - 2025)

Organogenesis Holdings has reported Capital Leases over the past 8 years, most recently at $12.8 million for Q4 2025.

  • Quarterly results put Capital Leases at $12.8 million for Q4 2025, up 1681.06% from a year ago — trailing twelve months through Dec 2025 was $12.8 million (up 1681.06% YoY), and the annual figure for FY2025 was $12.8 million, up 1681.06%.
  • Capital Leases for Q4 2025 was $12.8 million at Organogenesis Holdings, up from $2.1 million in the prior quarter.
  • Over the last five years, Capital Leases for ORGO hit a ceiling of $12.8 million in Q4 2025 and a floor of $98000.0 in Q2 2025.
  • Median Capital Leases over the past 4 years was $1.5 million (2024), compared with a mean of $3.2 million.
  • Biggest five-year swings in Capital Leases: plummeted 93.21% in 2021 and later surged 1681.06% in 2025.
  • Organogenesis Holdings' Capital Leases stood at $831000.0 in 2021, then soared by 127.2% to $1.9 million in 2023, then plummeted by 61.97% to $718000.0 in 2024, then surged by 1681.06% to $12.8 million in 2025.
  • The last three reported values for Capital Leases were $12.8 million (Q4 2025), $2.1 million (Q3 2025), and $98000.0 (Q2 2025) per Business Quant data.